Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: 2020 report. Available from: http://www.goldcopd.org. Accessed 311, 2020.
   Google Scholar
• JenkinsCR, CelliB, AndersonJA, et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J. 2012;39(1):38–45. doi:10.1183/09031936.0019461021737561
   PubMed Web of Science ®Google Scholar
• PunekarYS, MullerovaH, SmallM, et al. Prevalence and burden of dyspnoea among patients with chronic pulmonary obstructive disease in five European countries. Pulm Ther. 2016;2(1):59–72. doi:10.1007/s41030-016-0011-5
   Google Scholar
• Lonhala® Magnair® [prescribing information]. Lonhala^® Magnair^® [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; 6 2019.
   Google Scholar
• PhamS, FergusonGT, KerwinE, GoodinT, WheelerA, BauerA. In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution. J Aerosol Med Pulm Drug Deliv. 2018;31(3):162–169. doi:10.1089/jamp.2017.138429125918
   PubMed Web of Science ®Google Scholar
• KerwinE, DonohueJF, GoodinT, TosielloR, WheelerA, FergusonGT. Efficacy and safety of glycopyrrolate/eFlow ((R)) CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. Respir Med. 2017;132:238–250. doi:10.1016/j.rmed.2017.07.01128838685
   PubMed Web of Science ®Google Scholar
• DonaldsonGC, SeemungalTA, BhowmikA, WedzichaJA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. doi:10.1136/thorax.57.10.84712324669
   PubMed Web of Science ®Google Scholar
• SchmidtSA, JohansenMB, OlsenM, et al. The impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort study. BMJ Open. 2014;4(12):e006720. doi:10.1136/bmjopen-2014-006720
   PubMed Web of Science ®Google Scholar
• JonesPW. St. George’s respiratory questionnaire: MCID. Copd. 2005;2(1):75–79. doi:10.1081/COPD-20005051317136966
   PubMedGoogle Scholar
• WilkeS, JonesPW, MullerovaH, et al. One-year change in health status and subsequent outcomes in COPD. Thorax. 2015;70(5):420–425. doi:10.1136/thoraxjnl-2014-20569725782757
   PubMed Web of Science ®Google Scholar
• PalyVF, NayaI, GunsoyNB, et al. Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study. Int J Chron Obstruct Pulmon Dis. 2019;14:939–951. doi:10.2147/COPD.S18889831190781
   PubMed Web of Science ®Google Scholar
• SinghD, D’UrzoAD, ChuecosF, MunozA, Garcia GilE. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Respir Res. 2017;18(1):106. doi:10.1186/s12931-017-0583-028558833
   PubMed Web of Science ®Google Scholar
• SinghD, Maleki-YazdiMR, TombsL, IqbalA, FahyWA, NayaI. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413–1424. doi:10.2147/COPD.S10161227445468
   PubMed Web of Science ®Google Scholar
• GreulichT, KostikasK, GagaM, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. Int J Chron Obstruct Pulmon Dis. 2018;13:1229–1237. doi:10.2147/COPD.S15973229713156
   PubMed Web of Science ®Google Scholar
• AnzuetoAR, KostikasK, MezziK, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. Respir Res. 2018;19(1):121. doi:10.1186/s12931-018-0830-z29925383
   PubMed Web of Science ®Google Scholar
• Rodriguez-RoisinR. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(Suppl 5):398S–401S. doi:10.1378/chest.117.5_suppl_2.398S10843984
   PubMed Web of Science ®Google Scholar
• NagaiK, MakitaH, SuzukiM, et al. Differential changes in quality of life components over 5 years in chronic obstructive pulmonary disease patients. Int J Chron Obstruct Pulmon Dis. 2015;10:745–757. doi:10.2147/COPD.S7758625914531
   PubMed Web of Science ®Google Scholar
• OgaT, NishimuraK, TsukinoM, SatoS, HajiroT, MishimaM. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med. 2007;101(1):146–153. doi:10.1016/j.rmed.2006.04.00116713225
   PubMed Web of Science ®Google Scholar
• NayaIP, TombsL, MuellerovaH, ComptonC, JonesPW. Long-term outcomes following first short-term clinically important deterioration in COPD. Respir Res. 2018;19(1):222. doi:10.1186/s12931-018-0928-330453972
   PubMed Web of Science ®Google Scholar
• MahlerDA, WatermanLA, WardJ, GiffordAH. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. J Aerosol Med Pulm Drug Deliv. 2014;27(2):103–109. doi:10.1089/jamp.2013.103823745526
   PubMed Web of Science ®Google Scholar
• JanssensW, VandenBrandeP, HardemanE, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78–83. doi:10.1183/09031936.0002480717898020
   PubMed Web of Science ®Google Scholar
• Al-ShowairRA, TarsinWY, AssiKH, PearsonSB, ChrystynH. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101(11):2395–2401. doi:10.1016/j.rmed.2007.06.00817629471
   PubMed Web of Science ®Google Scholar
• SharmaG, MahlerDA, MayorgaVM, DeeringKL, HarshawO, GanapathyV. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. Chronic Obstr Pulm Dis. 2017;4(3):217–224. doi:10.15326/jcopdf.4.3.2017.018328848933
   PubMed Web of Science ®Google Scholar
• KerwinEM, DonohueJF, FergusonGT, GanapathyV, Ozol-GodfreyA, RajagopalanK. Satisfaction with the use of eFlow closed-system nebulizer in patients with moderate-to-very severe chronic obstructive pulmonary disease: findings from a long-term safety study. J Aerosol Med Pulm Drug Deliv. 2019;32(1):24–33. doi:10.1089/jamp.2018.147730457433
   PubMed Web of Science ®Google Scholar
• TashkinDP. A review of nebulized drug delivery in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2585–2596. doi:10.2147/COPD.S11403427799757
   PubMed Web of Science ®Google Scholar
• LangeP, CelliB, AgustiA, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med. 2015;373(2):111–122. doi:10.1056/NEJMoa141153226154786
   PubMed Web of Science ®Google Scholar
• FergusonGT, KerwinEM, DonohueJF, et al. Health-related quality of life improvements in moderate to very severe chronic obstructive pulmonary disease patients on nebulized glycopyrrolate: evidence from the GOLDEN studies. Chronic Obstr Pulm Dis. 2018;5(3):193–207. doi:10.15326/jcopdf.5.3.2017.017830584583
   PubMed Web of Science ®Google Scholar
• AnzuetoAR, VogelmeierCF, KostikasK, et al. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1325–1337. doi:10.2147/COPD.S13330728496316
   PubMed Web of Science ®Google Scholar